论重构国有企业的激励约束机制

国有企业激励约束机制的重建关系到国有企业的生存与发展 ,重建国有企业激励约束机制是一项复杂的系统工程 ,只有从所有权、委托代理及会计人和经营人员等方面去进行改革 ,进行公司治理 ,才能建立起有效的国有企业激励约束机制     

以"三个代表"重要思想为指导繁荣云南哲学社会科学事业

在建立社会主义市场经济、建设有中国特色社会主义的过程中 ,必须以“三个代表”的重要思想为指导 ,充分重视哲学社会科学研究的重大意义。云南省哲学社会科学研究在全省的经济社会发展中发挥了重要作用。进入 2 1世纪 ,新时期对云南省哲学社会科学研究提出了更高的要求 ,坚持“与时俱进” ,推进理论创新 ,才能使哲学社会科学研究更好地为党和政府决策服务 ,为建设云南民族文化大省服务     

Contents of Volume 19 (2000)

Volume Contents

Contents of Volume 19 (2000)     

Author Index

Authors Index

Author Index     

零工经济中个体就业动机探析 ——以北京市外卖骑手为例

随着数字技术的发展和人们生活、用餐习惯的改变，数字经济中的餐饮行业获得了较快发展，为劳动者创造了大量的就业机会。本研究基于外卖平台骑手的数据探讨数字零工经济下个体的就业动机。研究发现：大多数外卖骑手表面上是为了追求工作灵活性、经济收益和扩大社交网络而主动选择零工就业，但实际上，他们并没有在平台真正实现这三方面的诉求。劳动力市场结构转变让他们为了谋求生存而被动“挤入”,而非主动选择进入零工就业中。因此，针对劳动密集型平台就业群体，需要深入分析其选择零工就业的真正原因，才能在对其帮扶的政策制定和执行中，实现“对症下药”和“精准帮扶”。     

基于马克思劳动幸福理论的“劳动幸福问卷”设计及其信效度检验

劳动幸福是一种客观状态，对劳动幸福观测维度的测量有助于有针对性地提高劳动幸福程度。劳动幸福可以从四个观测维度进行测量，分别是劳动发展维度、劳动解放维度、劳动尊严维度以及劳动基础条件维度。这四个维度相互联系、互为因果，共同促进劳动幸福程度的提高。根据这样的理论建构，研究设计了"劳动幸福问卷”,对来自全国的样本进行了网络在线调查。分析结果显示，劳动幸福四维度之间具有正相关关系，符合本研究的理论建构。这说明“劳动幸福问卷”在总体上是可用的，是一个可靠和可信的研究工具。     

Medical devices; immunology and microbiology devices; classification of cystic fibrosis transmembrane conductance regulator gene mutation detection system. Final rule

The Food and Drug Administration (FDA) is classifying the cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection systems into class II (special controls). The special control that will apply to the device is the guidance document entitled "Class II Special Controls Guidance Document: CFTR Gene Mutation Detection Systems." The agency is classifying the device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the guidance document that will serve as the special control for the device.     

Possession, use, and transfer of select agents and toxins--reconstructed replication competent forms of the 1918 pandemic influenza virus containing any portion of the coding regions of all eight gene segments. Interim final rule

We are adding reconstructed replication competent forms of the 1918 pandemic influenza virus containing any portion of the coding regions of all eight gene segments to the list of HHS select agents and toxins. We are taking this action for several reasons. First the pandemic influenza virus of 1918-19 killed up to 50 million people worldwide, including an estimated 675,000 deaths in the United States. Also, the complete coding sequence for the 1918 pandemic influenza A H1N1 virus was recently identified, which will make it possible for those with knowledge of reverse genetics to reconstruct this virus. In addition, the first published study on a reconstructed 1918 pandemic influenza virus demonstrated the high virulence of this virus in cell culture, embryonated eggs, and in mice relative to other human influenza viruses. Therefore, we have determined that the reconstructed replication competent forms of the 1918 pandemic influenza virus containing any portion of the coding regions of all eight gene segments have the potential to pose a severe threat to public health and safety.     

Registration of food facilities under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule

The Food and Drug Administration (FDA) is issuing a final regulation that confirms the interim final rule entitled "Registration of Food Facilities Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002" (68 FR 58894, October 10, 2003 (interim final rule) as corrected by a technical amendment (69 FR 29428, May 24, 2004), and responds to comments submitted in response to the request for comments in the interim final rule. This final rule affirms the interim final rule's requirement that domestic and foreign facilities that manufacture/process, pack, or hold food for human or animal consumption in the United States be registered with FDA by December 12, 2003. The interim final rule implemented the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (the Bioterrorism Act), which requires domestic and foreign facilities to be registered with FDA by December 12, 2003. This final rule does not make any changes to the regulatory requirements established by the interim final rule.